TrialDrugs & aging2021

A Phase II, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Therapeutic Efficacy of Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease.

Michael Rosenbloom et al.PubMed ↗Publisher ↗

No numbers read from the abstract.